Investors & Media

Nov 23, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Nov 23, 2020 / Nov 23, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

11/12/20

BELLUS Health Reports Third Quarter 2020 Financial Results and Business Highlights
- Following a recent FDA meeting, the Phase 2b SOOTHE trial in refractory chronic cough patients remains on track to initiate in Q4 2020 - - The Phase 2 BLUEPRINT trial in chronic pruritus associated with atopic dermatitis remains on track to initiate in Q4 2020 - - Recently completed $40M...
Read More
11/10/20

BELLUS Health to Participate in Jefferies Virtual London Healthcare Conference
LAVAL, Quebec --(BUSINESS WIRE)--Nov. 10, 2020-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced...
Read More
10/22/20

BELLUS Health Closes US$40 Million Public Offering of Common Shares in Canada and the United States, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
LAVAL, Quebec --(BUSINESS WIRE)--Oct. 22, 2020-- BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced...
Read More